Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1480 participants.
Also called NCT03710291
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,480 participants
- Sponsor
- Tricida, Inc.
- Registry
-
NCT03710291 -
2018-001303-36
-
- Other papers using this trial's data
- VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Albania, Argentina, Armenia, Australia, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, France, Georgia, Hong Kong SAR China, Hungary, Israel, Italy, Malaysia, Mexico, Netherlands, North Macedonia, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Korea, Spain, Taiwan, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03710291. Randomized; quadruple masking; primary purpose treatment. Start 2018-11-20 (actual); primary completion 2022-08-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
- Acronym
- VALOR-CKD
- Condition
- Metabolic Acidosis
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- TRC101
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tricida, Inc.
Record details
- Record id
cardio:ct-nct03710291- Content hash
86a45b4afa25360ffab4e946abfa37cf9c785ecfb1be185ef25410f5db945137